Matinas BioPharma Holdings Inc Stock Other OTC
Equities
US5768101058
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 27 | Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024 | |
Mar. 27 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 44.87M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.63
x | P/E ratio 2025 * |
-1.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.47% |
Latest transcript on Matinas BioPharma Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Jerome Jabbour
FOU | Founder | 50 | 13-04-30 |
Keith Kucinski
DFI | Director of Finance/CFO | 55 | 19-01-02 |
Hui Liu
CTO | Chief Tech/Sci/R&D Officer | 56 | 20-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Herbert Conrad
FOU | Founder | 91 | 13-04-30 |
Natasha Giordano
BRD | Director/Board Member | 62 | 20-09-13 |
Eric Ende
CHM | Chairman | 55 | 17-04-02 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |